Production (Stage)
Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.76M | -7.51M | -5.94M | -6.01M | -6.04M |
| Total Depreciation and Amortization | 46.50K | 54.50K | 37.80K | 42.00K | 37.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.42M | 913.40K | 455.00K | 1.10M | -381.20K |
| Change in Net Operating Assets | -707.40K | 568.70K | -4.74M | -2.84M | 250.10K |
| Cash from Operations | -6.00M | -5.97M | -10.19M | -7.71M | -6.14M |
| Capital Expenditure | -169.00K | -44.30K | -42.30K | -10.80K | -6.80K |
| Sale of Property, Plant, and Equipment | -- | 600.00 | 0.00 | 28.50K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -169.00K | -43.80K | -42.30K | 17.70K | -6.80K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -4.60M | -4.50M | -20.50K |
| Issuance of Common Stock | 429.90K | 31.73M | 0.00 | 0.00 | 23.19M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 429.90K | 31.73M | -4.60M | -4.50M | 23.17M |
| Foreign Exchange rate Adjustments | 95.50K | -1.28M | 178.90K | -397.60K | -460.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.65M | 24.44M | -14.65M | -12.59M | 16.57M |